Intensity Therapeutics (INTS) Change in Accured Expenses (2022 - 2026)
Intensity Therapeutics' (INTS) quarterly Change in Accured Expenses came in at $87000.0 in Q1 2026, down 89.95% YoY from $866000.0 in Q1 2025, and up 163.04% on a QoQ basis from -$138000.0 in Q4 2025.
Intensity Therapeutics (INTS) Change in Accured Expenses (2022 - 2026) Analysis & Trends
Intensity Therapeutics (INTS) has 5 years of Change in Accured Expenses data on file, last reported at $87000.0 in Q1 2026.
- Quarterly Change in Accured Expenses fell 89.95% year-over-year to $87000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$419000.0 (down 1031.11% YoY) and the FY2025 annual result came in at $360000.0, up 115.87% from the prior year.
- Change in Accured Expenses advanced to $87000.0 in Q1 2026, from -$138000.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $3.2 million in Q4 2023 to a low of -$2.3 million in Q3 2023.
- A 5-year average of $34589.0 and a median of -$25500.0 in 2025 frame the typical range for Change in Accured Expenses.
- The widest YoY moves for Change in Accured Expenses: up 1248.52% in 2023, down 345.08% in 2023.
- Tracing INTS's Change in Accured Expenses over 5 years: stood at -$282189.0 in 2022, then surged by 1248.52% to $3.2 million in 2023, then sank by 117.53% to -$568000.0 in 2024, then soared by 75.7% to -$138000.0 in 2025, then surged by 163.04% to $87000.0 in 2026.
- The last three Change in Accured Expenses figures came in at $87000.0 (Q1 2026), -$138000.0 (Q4 2025), and $104000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Intensity Therapeutics | 12.99 Mn | 12.99 Mn | - | 226,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 226,000.00 |
| Jun 30, 2026 | 226,000.00 |
| Mar 31, 2026 | 87,000.00 |
| Mar 31, 2026 | 87,000.00 |
| Dec 31, 2025 | -138,000.00 |
| Dec 31, 2025 | -138,000.00 |
| Sep 30, 2025 | 104,000.00 |
| Sep 30, 2025 | 104,000.00 |
| Jun 30, 2025 | -472,000.00 |
| Jun 30, 2025 | -472,000.00 |
| Mar 31, 2025 | 866,000.00 |
| Mar 31, 2025 | 866,000.00 |
| Dec 31, 2024 | -568,000.00 |
| Dec 31, 2024 | -568,000.00 |
| Sep 30, 2024 | -896,000.00 |
| Sep 30, 2024 | -896,000.00 |
| Jun 30, 2024 | 643,000.00 |
| Jun 30, 2024 | 643,000.00 |
| Mar 31, 2024 | -1.45 Mn |
| Mar 31, 2024 | -1.45 Mn |